NCT01264328 - Study of the Combination of Panitumumab With Paclitaxel as First-line Treatment of Subjects With Head and Neck Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 9, 2011

Primary Completion Date

October 31, 2011

Study Completion Date

September 29, 2014

Conditions

Head and Neck Cancer

Interventions

DRUG

Panitumumab + paclitaxel

Paclitaxel 80 mg/m2 may be infused, intravenously, over one hour every week. Panitumumab will be administered every 2 weeks at a dose of 6 mg/kg, using a non pyrogenic low protein binding filter with a 0.20-0.22-μm pore size intravenously over 1 hour ± 15 minutes. Panitumumab will be administered prior to paclitaxel.

Trial Locations (12)

28922

Hospital Universitario Fundación Alcorcón, Madrid

31008

Hospital de Navarra, Pamplona

37007

Hospital Universitario de Salamanca, Salamanca

Unknown

Hospital Duran i Reynals, L'Hospitalet de Llobregat

Hospital de la Santa Creu i Sant Pau, Barcelona

Hospital General de Yagüe, Burgos

H. Virgen de las Nieves, Granada

Hospital Universitario 12 de Octubre, Madrid

Hospital General Universitario, Valencia

Hospital Universitario la Fe de Valencia, Valencia

Hospital Miguel Servet, Zaragoza

08036

Hospital Clínic i Provincial de Barcelona, Barcelona